Evidence map›Paper›PMID 28984303›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018

Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.

Catherine Zilberg, Matthew Weicai Lee, Bing Yu, Bruce Ashford, Spiridoula Kraitsek, Marie Ranson, Kerwin Shannon, Mark Cowley, N Gopalakrishna Iyer, Carsten E Palme and 5 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Role ofTranslational cancer research · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Reconceiving Perineural Invasion in Cutaneous Squamous Cell Carcinoma: From Biological to Histopathological Assessment.Pathobiology : journal of immunopathology, molecular and cellular biology · 2024
    Review
  10. Review
  11. Next-generation sequencing in dermatology.Frontiers in medicine · 2023
    Review
  12. Development of anFrontiers in oncology · 2023
    Article
  13. Review
  14. Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from squamous dysplastic precursors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  15. Review
  16. Article
  17. Article
  18. Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2021
    Review
  19. Article
  20. Molecular Profile of Advanced Cutaneous Squamous Cell Carcinoma.The Journal of clinical and aesthetic dermatology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Catherine ZilbergCentral Clinical School, The University of Sydney, Sydney, Australia.
Matthew Weicai LeeCentral Clinical School, The University of Sydney, Sydney, Australia.
Bing YuCentral Clinical School, The University of Sydney, Sydney, Australia.ORCID 0000-0001-6013-5220
Bruce AshfordIllawarra and Shoalhaven Local Health District (ISLHD), Wollongong, Australia.
Spiridoula KraitsekDepartment of Medical Genomics, Royal Prince Alfred Hospital, Sydney, Australia.
Marie RansonSchool of Biological Sciences, University of Wollongong, Wollongong, Australia.
Kerwin ShannonThe Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.ORCID 0000-0001-8538-3132
Mark CowleyKinghorn Cancer Centre and Garvan Institute of Medical Research, Sydney, Australia.
N Gopalakrishna IyerSinghealth/Duke-NUS Head and Neck Center, National Cancer Center Singapore (NCCS), Singapore.
Carsten E PalmeCentral Clinical School, The University of Sydney, Sydney, Australia.
Sydney Ch'ngCentral Clinical School, The University of Sydney, Sydney, Australia.
Tsu-Hui Hubert LowCentral Clinical School, The University of Sydney, Sydney, Australia.
Sandra O'TooleCentral Clinical School, The University of Sydney, Sydney, Australia.
Jonathan R ClarkCentral Clinical School, The University of Sydney, Sydney, Australia.
Ruta GuptaCentral Clinical School, The University of Sydney, Sydney, Australia.
The University of Sydney · AUUniversity of Wollongong · AUChris O’Brien Lifehouse · AUGarvan Institute of Medical Research · AURoyal Prince Alfred Hospital · AUSingHealth · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous squamous cell carcinoma is the second most prevalent malignancy, most frequently occurring in the head and neck (head and neck cutaneous squamous cell carcinoma). Treatment of locally advanced or metastatic disease is associated with functional morbidity and disfigurement. Underlying genetic mechanisms are poorly understood. Targeted sequencing of 48 clinically relevant genes was performed on DNA extracted from formalin-fixed and paraffin-embedded high-risk primary head and neck cutaneous squamous cell carcinomas that remained non-metastatic at minimum follow-up of 24 months. Associations of somatic mutations with clinicopathologic characteristics were evaluated and compared with those described in the literature for metastatic disease. Alterations in 44 cancer-associated genes were identified. TP53 was mutated in 100% of cases; APC, ATM, ERBB4, GNAQ, KIT, RB1 and ABL1 were altered in 60% of cases. FGFR2 mutations (40%) were exclusively seen in patients with perineural invasion. MLH1 mutations were exclusively seen in the two younger patients (<45 years). Lower incidences of NOTCH1 mutations were observed compared with that described in metastatic head and neck cutaneous squamous cell carcinoma in the literature. Somatic mutations susceptible to EGFR inhibitors, and other small molecular targeted therapeutics were seen in 60% of cases. This study provides insights into somatic mutations in non-metastatic, high-risk head and neck cutaneous squamous cell carcinoma and identifies potential therapeutic targets. Alterations in FGFR2 and NOTCH1 may have roles in local and distant disease progression.

Indexed as

MutationAdenomatous Polyposis Coli ProteinAdultAgedAged, 80 and overAtaxia Telangiectasia Mutated ProteinsFemaleGene Expression ProfilingGTP-Binding Protein alpha Subunits, Gq-G11Head and Neck NeoplasmsHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedNeoplasm StagingProto-Oncogene Proteins c-kitAdenomatous Polyposis Coli ProteinAPC protein, humanAtaxia Telangiectasia Mutated ProteinsATM protein, humanERBB4 protein, humanGNAQ protein, humanGTP-Binding Protein alpha Subunits, Gq-G11KIT protein, humanProto-Oncogene Proteins c-kitRB1 protein, humanReceptor, ErbB-4Retinoblastoma Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein Ligases

Identifiers

PMID28984303
OpenAlexW2763391293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.